Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Beacon Therapeutics (LSE:SYNC), a portfolio company of Syncona Limited, has announced promising interim results from the Phase II DAWN trial of laru-zova, its gene therapy designed to treat X-linked retinitis pigmentosa (XLRP). The results showed notable improvements in visual function, including better low luminance visual acuity and enhanced mean sensitivity. The therapy was also well-tolerated by participants, adding to its potential as a future treatment option for XLRP, a genetic condition that currently has no approved therapies.
This milestone represents a significant step forward for Beacon Therapeutics, opening up new avenues for funding and advancing the development of laru-zova towards a pivotal Phase II/III clinical trial. The therapy holds the potential to improve the lives of XLRP patients by addressing an unmet medical need.
About Syncona Limited
Syncona Limited is a leading life sciences investor focused on creating, developing, and scaling breakthrough healthcare companies. The company partners with academic founders and experienced management teams to advance transformative treatments for patients with high unmet medical needs. Syncona’s diversified portfolio includes a wide range of companies at various stages of development, across multiple therapeutic areas and modalities.
-
Average Daily Trading Volume: 632,101
-
Technical Sentiment Signal: Sell
